ABSTRACT
BACKGROUND/AIMS: The aim of this study was to identify the factors influencing mortality, morbidity and survival for gastric cancer in patients 80 years of age and older. METHODOLOGY: This retrospective study of gastric cancer in the elderly was conducted from 2003 to 2008. We examined demographic data, treatment, causes of death and their overall survival. RESULTS: On gastric cancer in the elderly, the stage IV was significantly higher in non-surgery group (47%) than in surgery group (12%). Moreover, non-surgery group had significantly more cardiac disease (p = 0.007) and previous stroke (p = 0.035) than surgery group. Differences in overall survival were statistically significant among stage I (p = 0.025) and stage II/III (p <0.001) patients. The other, the overall survival difference was not statistically significant between surgery group and non-surgery group, in stage IV (p = 0.05). CONCLUSIONS: In the study, age is not the only contraindication to resection for gastric cancer because when elderly patients undergo curative resection, they do not have a worse prognosis than without surgery group. In the elderly, the surgical strategy must be always modulated on the basis of preoperative comorbidities, the degree of the tumor spread, and the expected equality of life offered by a surgical procedure.
Subject(s)
Gastrectomy , Hospitals , Stomach Neoplasms/surgery , Age Factors , Aged, 80 and over , Chi-Square Distribution , Comorbidity , Contraindications , Gastrectomy/mortality , Humans , Japan/epidemiology , Kaplan-Meier Estimate , Neoplasm Staging , Patient Selection , Quality of Life , Retrospective Studies , Risk Factors , Stomach Neoplasms/mortality , Stomach Neoplasms/pathology , Time Factors , Treatment OutcomeABSTRACT
INTRODUCTION: Some of our patients showed a recurrence of adhesive small bowel obstruction (ASBO) with nonoperative management. The aim of this study was to evaluate the parameters predicting the recurrence of ASBO in patients managed with a long tube. METHODS: Of 234 patients with ASBO admitted from April 1998 to September 2002, a total of 91 who recovered with nonoperative management after long tube placement were enrolled in this retrospective clinical study. We divided them into two groups for follow-up: the recurrence group and the no-recurrence group. We compared baseline characteristics, the number of previous ASBO admissions, the number of abdominal operations, the interval from the onset of symptoms to long-tube insertion, the duration of long-tube placement, the type of the contrasted intestine through the long tube, the location of the long-tube tip, and the drainage volume through the long tube between the two groups. We then examined the cumulative recurrence rate. RESULTS: A significant difference was found in the number of previous ASBO admissions, the duration of long-tube placement (77 hours vs. 43 hours), the contrasted intestine through the long tube, and the location of the long-tube tip. By multivariate analysis, the duration of long-tube placement was an independent parameter predicting the recurrence of ASBO. CONCLUSIONS: These results suggest that the duration of long-tube placement might serve as a parameter for predicting recurrence of ASBO in patients managed with a long tube.
Subject(s)
Intestinal Obstruction/therapy , Intestine, Small , Intubation, Gastrointestinal/instrumentation , Adolescent , Adult , Aged , Aged, 80 and over , Contrast Media , Decompression, Surgical , Diatrizoate Meglumine , Drainage , Female , Humans , Intestinal Obstruction/diagnosis , Intestinal Obstruction/etiology , Male , Middle Aged , Multivariate Analysis , Recurrence , Regression Analysis , Tissue Adhesions/complicationsABSTRACT
BACKGROUND: TAOS1 (tumor amplified and overexpressed sequence 1) was recently cloned and found to be possibly important in driving the amplification of 11q13 in oral squamous cell carcinoma (SCC). MATERIALS AND METHODS: Quantitative RT-PCR was performed to determine the possible relationship between TAOS1 gene expression levels and clinicopathological features in esophageal SCC. RESULTS: TAOS1 overexpression was observed in 7 out of 38 (18%) esophageal SCCs and CCND1 overexpression was observed in 4 out of 38 (11%), suggesting that TAOS1 was more frequently overexpressed than CCND1 in esophageal SCC. The examination of the correlation of TAOS1 overexpression with the clinicopathological features revealed a significant difference in lymph node metastasis (p = 0.014) and a trend towards advanced TNM stages (p = 0.074). CONCLUSION: The present results suggest that TAOS1 might serve as a new marker for predicting the malignancy of esophageal SCC.
Subject(s)
Biomarkers, Tumor/biosynthesis , Carcinoma, Squamous Cell/metabolism , Esophageal Neoplasms/metabolism , Neoplasm Proteins/biosynthesis , Aged , Biomarkers, Tumor/genetics , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Cyclin D1/biosynthesis , Cyclin D1/genetics , Esophageal Neoplasms/genetics , Esophageal Neoplasms/pathology , Female , Gene Expression , Humans , Male , Middle Aged , Neoplasm Proteins/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , RNA, Ribosomal, 18S/biosynthesis , RNA, Ribosomal, 18S/genetics , Reverse Transcriptase Polymerase Chain ReactionSubject(s)
Colitis, Ulcerative/drug therapy , Cyclosporine/adverse effects , Cytomegalovirus Infections/complications , Disseminated Intravascular Coagulation/etiology , Immunosuppressive Agents/adverse effects , Adult , Antiviral Agents/therapeutic use , Colitis, Ulcerative/complications , Cyclosporine/therapeutic use , Cytomegalovirus Infections/drug therapy , Disseminated Intravascular Coagulation/drug therapy , Follow-Up Studies , Ganciclovir/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , MaleABSTRACT
BACKGROUND: It is important to seek the appropriate chemotherapy drugs to effectively eliminate colorectal cancers. To avoid unnecessary medication and uncomfortable side effects, it is important to estimate the chemosensitivity of cancers to 5-fluorouracil (5-FU) before chemotherapy. METHODS: We examined thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) gene expressions in 23 colorectal cancers, using quantitative reverse transcription-polymerase chain reaction (RT-PCR). We then evaluated the relationship between TS and DPD gene expression levels and the sensitivity of colorectal cancers to 5-FU, as determined by histoculture drug response assay (HDRA). RESULTS: A significant increase in the TS expression score was observed in 5-FU-sensitive colorectal cancers (0.57 +/- 0.19) compared to 5-FU-resistant ones (1.16 +/- 0.98; P = 0.029), whereas no significant differences in DPD expression scores were observed in 5-FU-sensitive colorectal cancers (0.86 +/- 1.19) compared to 5-FU-resistant ones (0.56 +/- 1.05; P = 0.603). CONCLUSIONS: TS mRNA may be useful as a predictor of the 5-FU chemosensitivity of colorectal cancers.
